**WHRI Website:**

**Research Project Template**

Please complete one form per research project/program you would like displayed on the WHRI website. This page will provide you with a space to help recruit participants, disseminate findings and showcase other knowledge translation activities resulting from the study. The content you provide in this form will be connected to the research team’s bios provided by the membership information. If any of these fields do not apply to this project, please leave them blank.

If there are supporting documents you would like embedded on the project page (i.e. consent forms) or if you have any questions regarding this form, please contact Nicole Prestley at Nicole.Prestley@cw.bc.ca or by phone **604-875-2424 ext 4956**.

|  |  |
| --- | --- |
| **Title:** (same as consent form) | A phase IIIb, open-label, multi-centre immunization study to evaluate the safety of GlaxoSmithKline (GSK) Biologicals’ HPV-16/18 L1 VLP AS04 vaccine administered intramuscularly according to a 0, 1, 6-month schedule in healthy female subjects who received the placebo control in the GSK HPV-015 study. |
| **Principal Investigator:** | Dr. Deborah Money |
| **Primary Contact:**(name, title, phone, email) | Melissa Watt, Research Coordinator604-875-2424, ext 4878mwatt@cw.bc.ca |
| **About the Study:**(100 words or less plain language summary) | Eligible participants have previously taken part in one of GSK Biologicals’ clinical studies on the HPV vaccine, the HPV-015 study, where they received the control vaccine. When their HPV-015 study participation was concluded, it was planned that they would be offered GSK Biologicals’ HPV vaccine as well.The purpose of this study is therefore to enable all women 46 years of age or older, who received the control vaccine in the HPV-015 study, to receive the HPV vaccine. In addition, participation in this study will allow collection of further safety data on the HPV vaccine. |
| **Why is this research important?** |  |
| **Study Status:**(e.g. recruiting, data analysis, manuscript development, complete) | Data collection |
| **Who can participate:**(short description, attach consent form) | Participants who:* Live in a country where GSK Biologicals’ HPV vaccine is not yet licensed for your age group (46 years of age or older) and have read and signed this informed consent form.
* Are free of obvious health problems as determined by the study doctor (investigator or personnel who conducts the study).
* Previously received the control vaccine in the HPV-015 study.
* Have a negative urine pregnancy test at the time of the vaccination and are not breastfeeding.
* Are not likely to become pregnant during the vaccination phase of the study.
 |
| **Study Results/Publication:** |  |
| **Co-Investigators:** | Dr. Simon DobsonDr. Julie van Schalkwyk |
| **Funded by:** | GlaxoSmithKline (GSK) |
| **Partners:** |  |
| **Other Attachments:**(e.g. Newsletters, videos) |  |